These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 24996555)

  • 21. Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach.
    Wald DS; Wald NJ
    J Eval Clin Pract; 2012 Jun; 18(3):612-5. PubMed ID: 21276141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
    Roy A; Naik N; Srinath Reddy K
    Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries.
    Dehghan M; Mente A; Teo KK; Gao P; Sleight P; Dagenais G; Avezum A; Probstfield JL; Dans T; Yusuf S;
    Circulation; 2012 Dec; 126(23):2705-12. PubMed ID: 23212996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fixed-dose combination treatment after stroke for secondary prevention in China: a national community-based study.
    Longde W; Ling Y; Yang H; Yi Z; Yongjun W; Xunming J; Xiaoyuan N; Qiumin Q; Li H; Yuming X; Mei L; Jiayi S; Jing L; Dong Z
    Stroke; 2015 May; 46(5):1295-300. PubMed ID: 25782466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospects for a cardiovascular disease prevention polypill.
    Dabhadkar KC; Kulshreshtha A; Ali MK; Narayan KM
    Annu Rev Public Health; 2011; 32():23-38. PubMed ID: 21219156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polypill: the evidence and the promise.
    Lonn E; Yusuf S
    Curr Opin Lipidol; 2009 Dec; 20(6):453-9. PubMed ID: 19884824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maximizing therapeutic envelope for prevention of cardiovascular disease: role of polypill.
    Sanz G; Fuster V
    Mt Sinai J Med; 2012; 79(6):683-8. PubMed ID: 23239207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease.
    Jowett S; Barton P; Roalfe A; Fletcher K; Hobbs FDR; McManus RJ; Mant J
    PLoS One; 2017; 12(9):e0182625. PubMed ID: 28873416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cut stroke in half: Polypill for primary prevention in stroke.
    Brainin M; Feigin V; Martins S; Matz K; Roy J; Sandercock P; Teuschl Y; Tuomilehto J; Wiseman A
    Int J Stroke; 2018 Aug; 13(6):633-647. PubMed ID: 29461155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polypill Variants (Quarter Pill Trials).
    Teo K; Yusuf S
    Am J Hypertens; 2018 Jun; 31(7):758-761. PubMed ID: 29554202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polypill Trials for Stroke Prevention-Main Results, Critical Appraisal, and Implications for US Population.
    Ibraheem M; Goldstein LB
    Curr Neurol Neurosci Rep; 2020 Apr; 20(5):10. PubMed ID: 32296941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Epidemiology and prevention of cardiovascular diseases].
    Jánosi A
    Orv Hetil; 2005 Apr; 146(15):683-8. PubMed ID: 15895792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular disease prevention using fixed dose pharmacotherapy in Iran: updated meta-analyses and mortality estimation.
    Sepanlou SG; Farzadfar F; Jafari E; Danaei G
    Arch Iran Med; 2012 Sep; 15(9):531-7. PubMed ID: 22924369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolution of the polypill concept and ongoing clinical trials.
    Castellano JM; Sanz G; Fuster V
    Can J Cardiol; 2014 May; 30(5):520-6. PubMed ID: 24786442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polypharmacotherapy for primary prevention of cardiovascular disease.
    Xavier D; Devereaux PJ; Goyal A; Pais P; Yusuf S
    Indian Heart J; 2008; 60(2 Suppl B):B29-33. PubMed ID: 19359761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges.
    ; Yusuf S; Attaran A; Bosch J; Joseph P; Lonn E; McCready T; Mente A; Nieuwlaat R; Pais P; Rodgers A; Schwalm JD; Smith R; Teo K; Xavier D
    Eur Heart J; 2014 Feb; 35(6):353-64. PubMed ID: 24288261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The feasibility of polypill for cardiovascular disease prevention in Asian Population.
    Sukonthasarn A; Chia YC; Wang JG; Nailes J; Buranakitjaroen P; Van Minh H; Verma N; Hoshide S; Shin J; Turana Y; Tay JC; Teo BW; Siddique S; Sison J; Zhang YQ; Wang TD; Chen CH; Kario K
    J Clin Hypertens (Greenwich); 2021 Mar; 23(3):545-555. PubMed ID: 33086429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.